Friday, 18 Oct 2019

You are here

Unmet Needs in Calcium Pyrophosphate Deposition Disease

Abhishek et al have written on the results of an international survey of crystal arthritis experts and identified the unmet needs  regarding calcium pyrophosphate crystal deposition (CPPD) - research, classification, diagnosis and management.

CPPD is a highly prevalent condition with a range of manifestations that may lead to pain, synovitis and joint damage, especially in the elderly.

In an effort to ascertain the unmet needs in CPPD, researchers surveyed members of the the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). From the 140 survey invitees, there were 26 respondents from 27 countries who provided prioritized answers regarding clinical phenotyping, diagnostic modalities, pathogenesis, stratified medicine, outcomes, and treatment.

Priority unmet needs included: 

  • The need and use of in vitor or animal CPPD models to better define CPPD mechanism paradigms and help guide new therapies.
  • The development of CPPD nomenclature and disease phenotype classification would greatly aid CPPD recognition, clinical research, and patient care and could include pragmatic new point-of-care crystal analytic approaches for detecting CPP crystals.
  • Unanswered questions include the uncertain clinical significance of CPP crystals in OA, or asymptomatic joints in the elderly.  Moreover, our inability to alter the course of crystal deposition is problematic.
  • They called for CPPD clinical research studies to define how and when articular CPPD does substantial harm.
  • Ideal therapeutic interventions (including intra-articular agents) need to be studied to limit CPP crystal deposition and associated inflammation,.

Advances in basic and clinical science in CPPD are needed and now possible. .

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.